<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
  <head><style>.sub-copy a:hover{text-decoration:underline !important}@font-face {}@font-face {}@font-face {}@media screen and (max-width: 400px){.narrow--dt{padding-left:0 !important;padding-right:0 !important}.narrow__2--dt{padding-left:20px !important;padding-right:20px !important}}@media (prefers-color-scheme: dark){body{background-color:#f6f9fc !important;color:black !important}center,.webkit{background-color:#ffffff !important}table{color:#4a4a4a !important}.transparent{background-color:transparent !important}}@media only screen and (min-width: 500px){.title-line{height:87px !important}.desired-break{display:block !important}.padding-right{padding-right:55px !important}}@media only screen and (max-width: 700px){.register-cap{display:block !important}}</style>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Fintepla</title>
    

    
  </head>
  <body style="margin: 0; padding: 0">
    <center class="wrapper" style="
        width: 100%;
        table-layout: fixed;
        background-color: #f6f9fc;
        padding-bottom: 40px;
      ">
      <div class="webkit" style="max-width: 600px; background-color: #ffffff">
        <table class="outer" style="
            width: 100%;
            max-width: 600px;
            margin: 0 auto;
            border-spacing: 0;
            font-family: Lato, Arial, sans-serif;
            color: #4a4a4a;
          ">
          
          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="
                      padding: 0;
                      background-color: #682b8d;
                      text-align: center;
                    ">
                    <p class="sub-copy" style="
                        font-size: 12px;
                        line-height: 18px;
                        color: #ffffff;
                        margin-left: auto;
                        margin-right: auto;
                        display: inline-block;
                        text-align: left;
                      ">
                      INTENDED FOR HEALTHCARE PROFESSIONALS IN THE UK ONLY <br />
                      Prescribing information and adverse event reporting can be found
                      <a href="https://www.zogenixresources.eu/UK-Fintepla-fenfluramine-Prescribing-Information.pdf" target="_blank" class="sub-copy" style="
                          font-size: 12px;
                          line-height: 18px;
                          color: #63585c;
                          color: #682b8d;
                          text-decoration: underline;
                          color: #ffffff;
                        ">here</a>
                    </p>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 30px;
                padding-bottom: 35px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0; vertical-align: top">
                    <img src="https://evrenzo.s3.eu-west-2.amazonaws.com/fintepla/main-logo.png" alt="" width="143" style="border: 0" />
                  </td>
                  <td style="padding: 0; vertical-align: top">
                    <img src="https://evrenzo.s3.eu-west-2.amazonaws.com/fintepla/zogenix_purple_new.png" alt="" width="111" style="border: 0; float: right" />
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow__2--dt" style="padding: 0; padding-left: 40px; padding-right: 40px">
              <table width="100%" style="
                  width: 100%;
                  border-spacing: 0;
                  /* background-color: #f5f2f7; */
                ">
                <tr>
                  <td style="padding: 0 0 20px 0">
                    <table style="width: 100%; border-spacing: 0">
                      <tr style="background-color: #f5f2f7">
                        <td class="narrow" style="
                            padding: 0;
                            padding-left: 20px;
                            padding-right: 20px;
                          ">
                          <div class="title-line" style="width:3px;background-color:#d23d56;height:107px"></div>
                        </td>
                        <td style="padding: 0; padding-right: 20px">
                          <p style="font-size: 22px; color: #682b8d; line-height: 1.25;">
                            <span class="desired-break" style="padding-right:0px">EXPANDING TREATMENT OPTIONS IN</span>
                            <span class="desired-break" style="padding-right:0px">DRAVET SYNDROME WITH FINTEPLA<sup><img src="https://storage.finervision.com/public/emailers/traingle.png" alt="triangle" /></sup></span>
                            <span class="desired-break" style="padding-right:0px">(FENFLURAMINE)*: <strong>THE EXPERTS&#x2019; VIEW</strong></span>
                          </p>
                        </td>
                      </tr>
                    </table>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow--dt" style="padding: 0; padding-left: 20px; padding-right: 20px">
              <img src="https://storage.finervision.com/public/emailers/banner_image_3.png" alt="Banner" width="600px;" style="border: 0; max-width: 100%" />
            </td>
          </tr>
          
          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 15px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Dear <span id="mailto-name"></span>,
              </p>
              <p class="copy padding-right" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Fintepla is an additional adjunctive treatment for Dravet syndrome.
              </p>
              <p class="copy padding-right" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Please find the agendas for our UK launch meetings below.
                Join us virtually or in person to hear our expert speakers
                share their views on the current unmet needs in
                Dravet syndrome.
              </p>
            </td>
          </tr>
          
          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0">
                <tbody class="transparent" style="background-color:transparent">
                  <tr>
                    <td style="
                        padding: 0;
                        padding-bottom: 20px;
                        text-align: center;
                        vertical-align: middle;
                      ">
                      <a href="https://www.nice.org.uk/guidance/gid-ta10373/documents/html-content-3" target="_blank" class="register-btn" style="
                          display: inline-block;
                          color: white;
                          background-color: #D23D56;
                          text-decoration: none;
                          font-size: 15px;
                          padding: 12px 32px;
                          border-width: 2px;
                          border-style: solid;
                          border-color: #D23D56;
                        ">CLICK HERE TO REGISTER FOR EITHER<br /> THE LONDON OR MANCHESTER MEETINGS</a>
                    </td>
                  </tr>

                </tbody>
              </table>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 20px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 12px;
                  color: #948A8D;
                ">
                *Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on
                therapy to other antiepileptic medicines for patients 2 years of age and older.<sup>1</sup>
              </p>
              <p class="copy" style="
                  font-size: 12px;
                  line-height: 25px;
                  color: #948A8D;
                  text-align: center;
                ">
                These promotional meetings are funded and organised by Zogenix, a part of UCB.
              </p>
            </td>
          </tr>

          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0;table-layout: fixed; background-color: #f5f2f7; padding: 20px 0 0 0">
                <tr>
                  <td colspan="2">
                    <p style="color: #682b8d;text-align: center;font-size: 20px; line-height: 0.3">
                      <strong>MANCHESTER</strong>
                    </p>
                    <p style="color: #682b8d;text-align: center; line-height: 0.4">
                      <strong>28th September 2022</strong>
                    </p>
                    <p style="color: #682b8d;text-align: center;line-height: 0.5">
                      Malmaison Hotel
                    </p>
                  </td>
                </tr>
              </table>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 10px;
                background-color: #f5f2f7">
              <table style="width: 100%;  border-spacing: 0;">
                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D; margin: 0;">
                      18:30
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Dinner
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:00&#x2013;19:20
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>Welcome and introduction</strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Sameer Zuberi (Chair)
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:20&#x2013;19:30
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Look to the future: What additional treatment options mean
                        for people with Dravet syndrome and their families
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Galia Wilson (Dravet Syndrome UK)
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:30&#x2013;19:50
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Current field of view: Where are we with the diagnosis and
                        management of Dravet syndrome?
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Dr Rhys Thomas
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:50&#x2013;20:10
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Broadening horizons: Fintepla (fenfluramine), an additional
                        treatment option for patients with Dravet syndrome
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Helen Cross
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D; margin: 0;">
                      20:10&#x2013;20:20
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Break
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      20:20&#x2013;20:40
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Widening the lens: Real-world clinical experience with Fintepla
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Adam Strzelczyk
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      20:40&#x2013;20:55
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Live panel Q&amp;A
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      All
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      20:55&#x2013;21:00
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Summary and meeting close
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Sameer Zuberi
                    </p>
                  </td>
                </tr>

              </table>
            </td>
          </tr>


          <tr>
              <td colspan="2" style="padding:1.5rem;"></td>
          </tr>


          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0;table-layout: fixed; background-color: #f7dbe0; padding: 20px 0 0 0">
                <tr>
                  <td colspan="2">
                    <p style="color: #682b8d;text-align: center;font-size: 20px; line-height: 0.3">
                      <strong>LONDON</strong>
                    </p>
                    <p style="color: #682b8d;text-align: center; line-height: 0.4">
                      <strong>29th September 2022</strong>
                    </p>
                    <p style="color: #682b8d;text-align: center;line-height: 0.5">
                      Park Plaza Victoria Hotel
                    </p>
                  </td>
                </tr>
              </table>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 10px;
                background-color: #f7dbe0">
              <table style="width: 100%;  border-spacing: 0;">
                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D; margin: 0;">
                      18:30
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Dinner
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:00&#x2013;19:20
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>Welcome and introduction</strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Helen Cross (Chair)
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:20&#x2013;19:30
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Look to the future: What additional treatment options mean
                        for people with Dravet syndrome and their families
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Galia Wilson (Dravet Syndrome UK)
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:30&#x2013;19:50
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Current field of view: Where are we with the diagnosis and
                        management of Dravet syndrome?
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Sanjay Sisodiya
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      19:50&#x2013;20:10
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Broadening horizons: Fintepla (fenfluramine), an additional
                        treatment option for patients with Dravet syndrome
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Helen Cross
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D; margin: 0;">
                      20:10&#x2013;20:20
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Break
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      20:20&#x2013;20:40
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Widening the lens: Real-world clinical experience with Fintepla
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Adam Strzelczyk
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      20:40&#x2013;20:55
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Live panel Q&amp;A
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      All
                    </p>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0 0 20px 0; vertical-align: top; float: left; width: 20%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      20:55&#x2013;21:00
                    </p>
                  </td>

                  <td style="padding: 0 0 20px 0; vertical-align: top; float: right; width: 78%;">
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      <strong>
                        Summary and meeting close
                      </strong>
                    </p>
                    <p class="sub-copy" style="color: #682B8D;margin: 0;">
                      Professor Helen Cross
                    </p>
                  </td>
                </tr>

              </table>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding-top: 15px;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Kind regards<br />
                Rep&apos;s Full Name<br />
                Rep&apos;s Title<br />
                Email address And Phone number<br />
              </p>
            </td>
          </tr>

          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0">
                <tbody class="transparent" style="background-color:transparent">
                <tr>
                  <td style="
                        padding: 0;
                        padding-bottom: 40px;
                        text-align: center;
                        vertical-align: middle;
                      ">
                    <a href="https://www.nice.org.uk/guidance/gid-ta10373/documents/html-content-3" target="_blank" class="register-btn" style="
                          display: inline-block;
                          color: white;
                          background-color: #D23D56;
                          text-decoration: none;
                          font-size: 15px;
                          padding: 12px 32px;
                          border-width: 2px;
                          border-style: solid;
                          border-color: #D23D56;
                        ">CLICK HERE TO REGISTER FOR EITHER<br /> THE LONDON OR MANCHESTER MEETINGS</a>
                  </td>
                </tr>

                </tbody>
              </table>
            </td>
          </tr>


          <tr>
            <td class="narrow" style="
                padding-right: 20px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0; text-align: center">
                    <img width="136" src="https://evrenzo.s3.eu-west-2.amazonaws.com/fintepla/zogenix_purple_new.png" alt="Zogenix Logo" style="border: 0" />
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 20px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0">
                    <p style="
                        font-size: 12px;
                        font-weight: bold;
                        color: #682b8d;
                        line-height: 15px;
                      ">
                      References:
                    </p>
                    <ol style="
                        padding-right: 20px;
                        padding-top: 0;
                        padding-left: 16px;
                        font-size: 12px;
                      ">
                      <li style="padding-left: 24px; line-height: 12px">
                        <p style="line-height: 12px">Fintepla Summary of Product Characteristics.
                        </p>
                      </li>
                    </ol>
                  </td>
                </tr>

                <tr>
                  <td style="padding: 0">
                    <p class="sub-copy" style="font-size: 12px; line-height: 18px; color: #63585c">
                      For any medical questions, please email
                      <a href="mailto:medinfo.eu@zogenix.com" style="color: #66575c; text-decoration: none">medinfo.eu@zogenix.com</a>
                    </p>
                  </td>
                </tr>
              </table>
            </td>
          </tr>


          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
              ">
              <p class="copy" style="
                  font-size: 12px;
                  line-height: 25px;
                  color: #66575c;
                ">
                The information in this email is confidential, is intended for the addressed recipient only and must not
                be copied, distributed or disclosed. Any subsequent action taken with this email, including forwarding
                is not the responsibility of UCB or its affiliates. If you are not the intended recipient of this email,
                you are hereby notified that any disclosure, copying, distribution or taking action in relation of the
                contents of this email is strictly prohibited and may be unlawful.

              </p>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  font-size: 12px;
                  line-height: 25px;
                  color: #66575c;
                ">
                This email is sent to <u>NN.NN@com.com</u> because you indicated that you are willing to receive occasional
                emails based on your preferences. If you do not wish to receive such emails in the future please send an
                email to <a style="color: #63585c" href="mailto:neurology.solutions@ucb.com">neurology.solutions@ucb.com</a> with UNSUBSCRIBE in the subject line.
              </p>
            </td>
          </tr>



          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 10px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0; vertical-align: top; float: left; width: 33.33%;">
                    <a href="https://www.zogenixresources.eu/Zogenix-Privacy-Policy-Master.pdf" target="_blank" style="color: #63585c"><p class="sub-copy" style="font-size: 12px; line-height: 18px; ">Privacy policy</p></a>
                  </td>

                  <td style="padding: 0; vertical-align: top; float: left; width: 33.33%;">
                    <p class="sub-copy" style="font-size: 12px; line-height: 18px; color: #63585c; text-align: center">
                      GB-P-FA-DS-2200014
                    </p>
                  </td>

                  <td style="padding: 0; vertical-align: top; float: left; width: 33.33%;">
                    <p class="sub-copy" style="font-size: 12px; line-height: 18px; color: #63585c; text-align: right">
                      July 2022
                    </p>
                  </td>

                </tr>
              </table>
            </td>
          </tr>


          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  font-size: 12px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Fintepla<img src="https://storage.finervision.com/public/emailers/traingle.png" alt="triangle" />(fenfluramine) Prescribing information
                <a style="color: #63585c;white-space: nowrap;" href="#" target="_blank">Please refer to the full Summary of Product Characteristics (SmPC) before prescribing.</a>
              </p>
            </td>
          </tr>



          <tr>
            <td class="narrow" style="padding: 0; padding-left: 20px; padding-right: 20px">
              <p class="sub-copy footer-box" style="
                  font-size: 12px;
                  line-height: 18px;
                  color: #63585c;
                  max-width: 560px;
                  border-width: 1px;
                  border-style: solid;
                  border-color: #63585c;
                  padding-top: 20px;
                  padding-bottom: 20px;
                  padding-right: 43px;
                  padding-left: 43px;
                  text-align: center;
                ">
                Adverse events should be reported. Reporting forms and
                information can be found at
                <a href="https://yellowcard.mhra.gov.uk/" target="_blank" style="color: #682b8d; text-decoration: none">https://yellowcard.mhra.gov.uk/</a>
                or search for MHRA Yellow Card in the Google Play or Apple App
                Store. Adverse events should also be reported to Zogenix
                International Limited on
                <a href="tel:+448000608767" style="color: #682b8d; text-decoration: none">0800 060 8767</a>
                or email
                <a href="mailto:medinfo.eu@zogenix.com" style="color: #682b8d; text-decoration: none">medinfo.eu@zogenix.com</a>.
              </p>
            </td>
          </tr>
        </table>
      </div>
    </center>
  </body>
</html>
